依达赛珠单抗逆转达比加群酯致脑出血一例药学监护

Pharmaceutical care of Idarucizumab treatment with the intracerebral hemorrhage induced by Dabigatran:a case report

心房颤动患者常口服抗凝药预防静脉血栓栓塞和脑卒中的同时也会增加出血的风险。本文报告1例临床药师参与达比加群酯治疗非瓣膜性房颤患者致脑出血后,紧急使用依达赛珠单抗逆转的药物治疗过程,分析整个过程不良反应发生的原因及相关因素,并协助医师制订重启抗凝方案,同时实施药学监护,保障了患者安全合理用药。

Patients with atrial fibrillation often take oral anticoagulants to prevent venous thromboembolism and stroke,which increases the risk of bleeding.In this paper,clinical pharmacists analyzed the course of emergency administration of Idarucizumab in a patient with Dabigatran-induced cerebral hemorrhage,and analyzed the causes and related factors of adverse reactions in the whole process,and assist physicians to make a restart anticoagulation program.The implementation of pharmaceutical care to ensure the safety and rational drug use of patients.